| The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118) (NCT00832624) | Merck Sharp & Dohme LLC | 2008-11-26 |
| MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) (NCT00797667) | Merck Sharp & Dohme LLC | 2008-11-12 |
| Phase IIB 2-Period Crossover Polysomnography Study in Participants With Primary Insomnia (MK-4305-006) (NCT00792298) | Merck Sharp & Dohme LLC | 2008-11-05 |
| Safety and Efficacy Study of Posaconazole vs. Fluconazole for Prevention of Invasive Fungal Infection (P05387 AM1)(COMPLETED) (NCT00811928) | Merck Sharp & Dohme LLC | 2008-11-01 |
| MK-1006 Single Dose Study in Japanese Type 2 Diabetes Patients (MK-1006-005) (NCT00791661) | Merck Sharp & Dohme LLC | 2008-11-01 |
| Treatment With Infliximab in a Medical Setting (Study P05587) (NCT00752622) | Merck Sharp & Dohme LLC | 2008-11-01 |
| Hemodynamic Effects of Rolofylline in the Treatment of Patients With Heart Failure (7418-503) (NCT00729222) | Merck Sharp & Dohme LLC | 2008-11-01 |
| Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113) (NCT01472341) | Merck Sharp & Dohme LLC | 2008-11-01 |
| A Study of Single Dose MK-3614 (MK-3614-001)(COMPLETED) (NCT01104545) | Merck Sharp & Dohme LLC | 2008-11-01 |
| A Pharmacokinetics/Pharmacodynamics Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104AM2)(COMPLETED) (NCT00797745) | Merck Sharp & Dohme LLC | 2008-11-01 |
| Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551) (NCT00811642) | Merck Sharp & Dohme LLC | 2008-11-01 |
| Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED) (NCT00751179) | Merck Sharp & Dohme LLC | 2008-11-01 |
| A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) (NCT00779584) | Merck Sharp & Dohme LLC | 2008-10-17 |
| Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) (NCT00750919) | Merck Sharp & Dohme LLC | 2008-10-07 |
| Study to Evaluate Efficacy of Odanacatib (MK-0822) on Bone Mineral Density (BMD) and Bone Micro-architecture and Overall Safety in Postmenopausal Women (MK-0822-031) (NCT00729183) | Merck Sharp & Dohme LLC | 2008-10-02 |
| Temozolomide as a Prophylaxis Against Brain Recurrence in Participants With Metastatic Breast Cancer (P05225 AM2) (NCT00638963) | Merck Sharp & Dohme LLC | 2008-10-02 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK8245 (8245-004)(COMPLETED) (NCT00790556) | Merck Sharp & Dohme LLC | 2008-10-01 |
| Comparing 4.0 mg.Kg-1 Sugammadex With Placebo in the Reversal of Profound Neuromuscular Blockade (P05767) (NCT00758485) | Merck Sharp & Dohme LLC | 2008-10-01 |
| A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055) (NCT00764946) | Merck Sharp & Dohme LLC | 2008-10-01 |
| Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED) (NCT00781846) | Merck Sharp & Dohme LLC | 2008-10-01 |
| Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED) (NCT00767000) | Merck Sharp & Dohme LLC | 2008-10-01 |
| Assessment of Long-Term Infliximab for Psoriasis (P05319) (NCT00779675) | Merck Sharp & Dohme LLC | 2008-10-01 |
| Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED) (NCT00848484) | Merck Sharp & Dohme LLC | 2008-10-01 |
| Januvia Re-examination Study (MK-0431-181) (NCT01062048) | Merck Sharp & Dohme LLC | 2008-10-01 |
| A Study of Absorption, Metabolism, Excretion and Mass Balance After a Single Dose Administration of MK-0941 (MK-0941-016)(COMPLETED) (NCT00912002) | Merck Sharp & Dohme LLC | 2008-10-01 |
| Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002) (NCT00777959) | Merck Sharp & Dohme LLC | 2008-10-01 |
| A Study of Dalotuzumab (MK-0646) in Breast Cancer Patients (MK-0646-013) (NCT00759785) | Merck Sharp & Dohme LLC | 2008-09-30 |
| Comparison of 4.0 mg/kg Sugammadex at 1-2 Post Tetanic Counts (PTC) in Renal or Control Patients (19.4.328)(P05769) (NCT00702715) | Merck Sharp & Dohme LLC | 2008-09-24 |
| MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2) (NCT00722371) | Merck Sharp & Dohme LLC | 2008-09-05 |
| A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) (NCT00768521) | Merck Sharp & Dohme LLC | 2008-09-03 |
| A Study of Immune Cells in Patients With Rheumatoid Arthritis During Different Types of Anti-TNF Alpha Treatments (Study P05521) (NCT00724672) | Merck Sharp & Dohme LLC | 2008-09-01 |
| MK0633 Single Dose Study in Japanese Asthmatic Children Aged 12 to Less Than 16 Years (0633-028) (NCT00768170) | Merck Sharp & Dohme LLC | 2008-09-01 |
| A Placebo-Controlled Study of INS117548 Ophthalmic Solution in Subjects With Glaucoma (P08650) (NCT00767793) | Merck Sharp & Dohme LLC | 2008-09-01 |
| A Study to Determine the Safety and Efficacy of Once Daily Raltegravir Compared to Twice Daily Raltegravir (MK-0518-071) (NCT00745823) | Merck Sharp & Dohme LLC | 2008-09-01 |
| A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED) (NCT00757939) | Merck Sharp & Dohme LLC | 2008-09-01 |
| A Study of the Effects of Oral Prednisone in Patients With Rheumatoid Arthritis (MK0000-088) (NCT00746512) | Merck Sharp & Dohme LLC | 2008-09-01 |
| A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029) (NCT00692458) | Merck Sharp & Dohme LLC | 2008-09-01 |
| A Study of MK-3009 in Japanese Patients With Skin or Blood Stream Infections Caused by Methicillin-resistant Staphylococcus Aureus (MK-3009-002) (NCT00770341) | Merck Sharp & Dohme LLC | 2008-09-01 |
| A Study to Compare Methodologies for Assessing Glucose-Dependent Insulin Secretion (0000-104)(COMPLETED) (NCT00782418) | Merck Sharp & Dohme LLC | 2008-09-01 |
| Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082) (NCT00664287) | Merck Sharp & Dohme LLC | 2008-09-01 |
| MK-0941 Multiple Dose Study in Japanese Patients With Type 2 Diabetes (MK-0941-011). (NCT00754130) | Merck Sharp & Dohme LLC | 2008-09-01 |
| A Study to Assess the Effects of MK0822 in Prolonging Time to First Bone Metastasis in Men With Castration-Resistant Prostate Cancer (0822-030) (NCT00691899) | Merck Sharp & Dohme LLC | 2008-09-01 |
| Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) (NCT00483704) | Merck Sharp & Dohme LLC | 2008-08-14 |
| Study of Dalotuzumab (MK-0646) in Adults With Solid Tumors (MK-0646-009) (NCT00694356) | Merck Sharp & Dohme LLC | 2008-08-04 |
| Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED) (NCT00718237) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED) (NCT00705432) | Merck Sharp & Dohme LLC | 2008-08-01 |
| A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED) (NCT00717860) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Plasma Levels of MK0633 in Children Ages 6-12 (0633-023) (NCT00751413) | Merck Sharp & Dohme LLC | 2008-08-01 |
| A Study to Evaluate the Safety and Immunogenicity of V710 in Adults With Kidney Disease on Hemodialysis (V710-005)(COMPLETED) (NCT00572910) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6) (NCT00739830) | Merck Sharp & Dohme LLC | 2008-08-01 |
| A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) (NCT00753415) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Evaluate the Utility of 18FDG-PET as a Tool to Quantify Atherosclerotic Plaque (MK-0000-081 AM3)(COMPLETED) (NCT00703261) | Merck Sharp & Dohme LLC | 2008-08-01 |
| A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED) (NCT00758680) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) (NCT00771472) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED) (NCT00708500) | Merck Sharp & Dohme LLC | 2008-08-01 |
| A Study of the Kinetics of a 13C-Cholesterol Infusate in Healthy Male Subjects (0000-108)(COMPLETED) (NCT01101763) | Merck Sharp & Dohme LLC | 2008-08-01 |
| Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007) (NCT00704184) | Merck Sharp & Dohme LLC | 2008-07-25 |
| Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705) (NCT00725725) | Merck Sharp & Dohme LLC | 2008-07-23 |
| An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED) (NCT00496626) | Merck Sharp & Dohme LLC | 2008-07-20 |
| A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081) (NCT00730275) | Merck Sharp & Dohme LLC | 2008-07-18 |
| Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699) (NCT00724932) | Merck Sharp & Dohme LLC | 2008-07-16 |
| Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) (NCT00724451) | Merck Sharp & Dohme LLC | 2008-07-01 |
| A Combination Study With Ridaforolimus (MK8669) and Dalotuzumab (MK0646) in Patients With Advanced Cancer (8669-004) (NCT00730379) | Merck Sharp & Dohme LLC | 2008-07-01 |
| Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183) (NCT00617123) | Merck Sharp & Dohme LLC | 2008-07-01 |
| A Study to Evaluate Methodologies for Measuring Swelling of the Leg and Ankle (MK-0000-106)(COMPLETED) (NCT00789321) | Merck Sharp & Dohme LLC | 2008-07-01 |
| Oral Deforolimus With Trastuzumab for Patients With HER2-positive Trastuzumab-Refractory Metastatic Breast Cancer (8669-009) (NCT00736970) | Merck Sharp & Dohme LLC | 2008-07-01 |
| SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) (NCT00732810) | Merck Sharp & Dohme LLC | 2008-07-01 |
| Single-Dose Escalation Study of IDX184 in Healthy Volunteers (MK-2355-002) (NCT00730431) | Merck Sharp & Dohme LLC | 2008-07-01 |
| ATHENAS - Retrospective Study of Compliance in Chronic Hepatitis C With Pegylated Interferon Alfa-2b/Ribavirin in Brazil (P05632) (NCT00856024) | Merck Sharp & Dohme LLC | 2008-07-01 |
| MK3207 for Treatment of Acute Migraines (3207-005) (NCT00712725) | Merck Sharp & Dohme LLC | 2008-07-01 |
| Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN) (NCT00704951) | Merck Sharp & Dohme LLC | 2008-07-01 |
| Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572) (NCT00686725) | Merck Sharp & Dohme LLC | 2008-06-24 |
| A Study of MK-6213 Co-Administered With Atorvastatin in Participants With Hypercholesterolemia (MK-6213-006) (NCT00687271) | Merck Sharp & Dohme LLC | 2008-06-14 |
| Study of Ridaforolimus (MK-8669) in Participants With Solid Tumors (MK-8669-003)(COMPLETED) (NCT00694083) | Merck Sharp & Dohme LLC | 2008-06-10 |
| Efficacy and Safety Trial to Evaluate the Effect of SCH 497079 on Weight in Obese and Overweight Participants (Study P05483)(COMPLETED) (NCT00642993) | Merck Sharp & Dohme LLC | 2008-06-09 |
| A Study to Evaluate the Effect of Analgesics on a Walking Model of Knee Pain (0000-105)(COMPLETED) (NCT00772967) | Merck Sharp & Dohme LLC | 2008-06-01 |
| A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004) (NCT00847197) | Merck Sharp & Dohme LLC | 2008-06-01 |
| Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539) (NCT00730912) | Merck Sharp & Dohme LLC | 2008-06-01 |
| Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363) (NCT00688467) | Merck Sharp & Dohme LLC | 2008-06-01 |
| A Study to Evaluate the Effect of Famotidine and Omeprazole on MK0518 (Raltegravir) Pharmacokinetics in Human Immunodeficiency Virus (HIV)-Infected Patients (0518-054) (NCT01000818) | Merck Sharp & Dohme LLC | 2008-06-01 |
| A Study of MK0140 in Diabetic Patients With Macular Edema (0140-001) (NCT00692614) | Merck Sharp & Dohme LLC | 2008-06-01 |
| Diagnostic Criteria in the Diagnosis of Spinal Spondyloarthropathies in Patients With Chronic Low Back Pain (Study P05320)(COMPLETED) (NCT00726765) | Merck Sharp & Dohme LLC | 2008-06-01 |
| Zostavax® at Minimum Release Specification Approaching Expiry (V211-044) (NCT00681031) | Merck Sharp & Dohme LLC | 2008-05-14 |
| Observational Data Analysis in EuroSIDA (MK-0518-058) (NCT01078233) | Merck Sharp & Dohme LLC | 2008-05-05 |
| A Study to Test the Safety and Efficacy of Sitagliptin Compared to Glimepiride in Patients With Type 2 Diabetes on a Stable Dose of Metformin (0431-803)(COMPLETED) (NCT00701090) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Journey for Control of Diabetes Study (0431-111) (NCT00652509) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) (NCT00705224) | Merck Sharp & Dohme LLC | 2008-05-01 |
| A Study to Evaluate the Safety, Tolerability and Plasma Concentration Profiles of MK0633 in Asthmatic Children Aged 12 to Less Than 16 Years (0633-019) (NCT00646789) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774) (NCT00675792) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Neutrophilic Asthma Study With Navarixin (MK-7123, SCH 527123) (MK-7123-017)(COMPLETED) (NCT00632502) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Study of the Effect of SCH 900538 on Congestion in Subjects With Seasonal Allergic Rhinitis (Study P05031)(COMPLETED) (NCT00673062) | Merck Sharp & Dohme LLC | 2008-05-01 |
| A Study of the Effect of Estrogen on Estrogen Receptor Biomarkers in Healthy Postmenopausal Women (0000-094)(COMPLETED) (NCT00799708) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021) (NCT00496054) | Merck Sharp & Dohme LLC | 2008-05-01 |
| Effect of SCH 497079 on Metabolic Parameters and Influence of Race/Ethnic Origin on Therapeutic Response (Study P05338)(COMPLETED) (NCT00673465) | Merck Sharp & Dohme LLC | 2008-04-17 |
| A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579) (NCT01716234) | Merck Sharp & Dohme LLC | 2008-04-17 |
| Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002) (NCT00670488) | Merck Sharp & Dohme LLC | 2008-04-15 |
| Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) (NCT00723645) | Merck Sharp & Dohme LLC | 2008-04-01 |
| A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED) (NCT00757601) | Merck Sharp & Dohme LLC | 2008-04-01 |
| Dialysis of Sugammadex in Participants With Severe Renal Impairment (Study 19.4.333) (P05773) (NCT00656799) | Merck Sharp & Dohme LLC | 2008-04-01 |
| Safety and Efficacy Pilot Study of AzaSite® for Four Weeks in Subjects With Blepharitis (NCT00656539) | Merck Sharp & Dohme LLC | 2008-04-01 |